SCHEMBL30216757

SCHEMBL30216757

N=C(N)NCCC[C@H](NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 9/20 0.46
▸ NPY1R P25929 6/20 0.46
▸ NPY2R P49146 4/20 0.46
▸ NPY5R Q15761 4/20 0.46
▸ C5AR1 P21730 1/20 0.45
▸ APLNR P35414 2/20 0.45
▸ GLP1R P43220 1/20 0.43
▸ SCTR P47872 1/20 0.43
▸ KISS1R Q969F8 4/20 0.42
▸ QRFPR Q96P65 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29913275 1.00 NPY4R (0.46) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL29958548 0.94 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL30152128 0.94 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL29420164 0.94 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL29461968 0.94 NPY4R (0.46) NPY4RNPY1RNPY2RNPY5RKISS1R
SCHEMBL30948383 0.93 NPY4R (0.45) NPY4RNPY1RNPY2RNPY5RGLP1R
SCHEMBL29464056 0.92 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL31252942 0.92 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL29591109 0.92 NPY4R (0.44) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL30475878 0.91 NPY4R (0.46) NPY4RNPY1RNPY2RNPY5RGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110225922-B Agents for promoting angiogenesis and methods and uses thereof 血管免疫治疗公司 2023-09-12 — — CN disclosed
CN-115666543-A Coronavirus therapeutic agents and methods of treatment 血管免疫治疗公司 2023-01-31 — — CN disclosed
Send feedback